Paclitaxel plus ritonavir - Modra Pharmaceuticals

Drug Profile

Paclitaxel plus ritonavir - Modra Pharmaceuticals

Alternative Names: ModraPac 005; ModraPac 005/r

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Modra Pharmaceuticals
  • Class Amides; Antineoplastics; Carbamates; Diterpenes; Paclitaxels; Small molecules; Taxanes; Thiazoles
  • Mechanism of Action Angiogenesis inhibitors; Cytochrome P 450 enzyme system inhibitors; P-glycoprotein inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 02 Aug 2017 Chemical structure information added
  • 22 Jun 2017 Phase-I clinical trials in Cancer in Netherlands (PO) (Modra Pharmaceuticals pipeline, June 2017)
  • 22 Jun 2017 Modra Pharmaceuticas has patent protection for Modulated Oral Drug Absorption technology worldwide (Modra Pharmaceuticals website, June 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top